Qurient Demonstrates Efficacy and Safety of Mocaciclib Phase 1 Across Breast, Prostate and Pancreatic Cancers
Predicted impact: Low
Phase 1 data already reported via ESMO unveiling within the last 14 days; no new size.
Qurient큐리언트
115180 · KOSDAQ · ₩115180 · 큐리언트
₩17,970▼ ₩470 (2.55%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y +1.44%
- Market cap
- ₩674B
- Enterprise value
- ₩682B
- P/E
- —
- P/B
- 39.2×
- Dividend yield
- 0.0%
- ROE
- −222.9%
- Net margin
- −543.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.0% from the high
₩13,663Today: ₩17,000 – ₩18,530₩59,972
Returns
- 1W−17.0%
- 1M−16.4%
- 3M+24.5%
- 6M−52.0%
- YTD−37.7%
- 1Y+1.4%
- Volume today
- 150,500
- 1.0× the 20-day average
- Traded today
- ₩2.6B
- Listed shares
- 37,534,151
- EPS (12 months)
- −₩1,022
- Earnings yield −5.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headline reports positive early trial results for its cancer drug. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-16.6% over the last month; the price is below its 20-day average.
- News impactSome10 news items and filings in two weeks; 0 rated high impact, 5 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 28: buy ₩1.2B at the close (37.6% of 20-day average trading value)
On its 36 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 22.5% of trading value and pointed the same way 23 of 36 times.
- 2× KODEX KOSDAQ150 Leverage ₩1B
- -1× KODEX KOSDAQ150 Futures Inverse ₩59M
- 2× TIGER KOSDAQ150 Leverage ₩53M
- 2× RISE KOSDAQ150 Futures Leverage ₩10M
- -1× TIGER KOSDAQ150 Futures Inverse ₩1.9M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.3%
- KODEX KOSDAQ150 Leverage2×0.3%
- TIGER KOSDAQ1500.3%
- RISE KOSDAQ1500.3%
- TIGER KOSDAQ150 Leverage2×0.3%
- ACE KOSDAQ 1500.3%
- KIWOOM KOSDAQ1500.3%
- SOL KOSDAQ1500.3%
Estimated from the funds' index or underlying stock.
Qurient stock overview
Qurient (큐리언트, KRX: 115180) is listed on KOSDAQ, in the Biotech & Pharma sector. Curient is a Korean new-drug development biotech, established with government and international investment and spun off from the Korean Institute of Pasteur to commercialize its research. Its shares closed at ₩17,970 on Oct 28, 2026, down 2.55% on the day, giving it a market value of ₩674B.
Key facts
- Market cap
- ₩674B
- Sector
- Biotech & Pharma
- Latest price change
- −2.55%
- As of
- Oct 28, 2026
- Main business
- Curient is a Korean new-drug development biotech, established with government and international investment and spun off from the Korean Institute of Pasteur to commercialize its research.
Quick answers about Qurient
- What does Qurient do?
- Curient is a Korean new-drug development biotech, established with government and international investment and spun off from the Korean Institute of Pasteur to commercialize its research. It develops first-in-class cancer, antibiotic, and anti-inflammatory drug candidates, including mocaciclib (Q901), a CDK7 inhibitor being tested in the United States and Korea, and also runs a prescription and over-the-counter drug distribution business. Its drug development is conducted in the United States and Korea, and it is partnered with MSD (Merck) for combination therapy with Keytruda.
- What is the market cap of Qurient?
- The market capitalisation of Qurient was ₩674B at the close on Oct 28, 2026.
- Who are the largest shareholders of Qurient?
- According to the latest official filings, the largest reported holders are UAMCO Keystone Structural Innovation Corporate Financial Stability Private Equity Fund (19.80%, as of Aug 5, 2026); Dongkoo Bio & Pharma (19.40%, as of Aug 4, 2026); Institut Pasteur Korea (4.33%, as of Oct 29, 2024).
- When is the next earnings report from Qurient?
- Korean companies rarely announce results dates in advance. Based on when Qurient filed the same report in past years, its next 3q results is expected between Nov 9, 2026 and Nov 14, 2026.
- Does the National Pension Service own Qurient?
- Yes. The National Pension Service held 3.88% of Qurient shares as of Dec 31, 2025.
Company profile
Curient is a Korean new-drug development biotech, established with government and international investment and spun off from the Korean Institute of Pasteur to commercialize its research. It develops first-in-class cancer, antibiotic, and anti-inflammatory drug candidates, including mocaciclib (Q901), a CDK7 inhibitor being tested in the United States and Korea, and also runs a prescription and over-the-counter drug distribution business. Its drug development is conducted in the United States and Korea, and it is partnered with MSD (Merck) for combination therapy with Keytruda.
Written by AI from the company's latest annual report.
- Korean name
- 큐리언트
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 남기연
- Founded
- Jul 2008
- Listed
- Feb 2016
- Listed shares
- 37,534,151
- Fiscal year ends
- Month 12
- Website
- www.qurient.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
[Today's Market Calendar] Curient, MH Ethanol, Duobac and Others
Predicted impact: Low
Curient unveils Phase 1 data for 'mocaciclib' at ESMO: "Worked in terminal cancer patients who failed existing treatments"
Predicted impact: Medium
Phase 1 cancer data at ESMO; tiny revenue base, but a rights offering is pending, so data matters.
Recent filings
See all- Ex-Rights Date (Rights Offering)Oct 16, 2026
- Determination of Issue Price for First Tranche of Rights OfferingOct 16, 2026
- ProspectusOct 16, 2026
- Terms set: Securities registration statementOct 16, 2026
- Amended: Rights offering (paid-in capital increase) decisionOct 16, 2026
Titles in Korean until English translations are added.
Also known as: Qurient / 큐리언트 / 115180 / KRX:115180
Source: KRX statistical information